INTERVIEW: Dong-A Seeks Partners For Global Expansion Push
This article was originally published in PharmAsia News
Executive Summary
With a goal of becoming a truly global biopharma firm, Dong-A is now stepping up its R&D efforts like many other leading South Korean pharma companies. In an interview with PharmAsia News, a senior company executive talks about strategies for overseas business development including plans for biosimilars and original new drug candidates.
You may also be interested in...
AbbVie Picks Up Dong-A Candidate As It Makes Immuno-Onc Inroads
Dong-A ST has scored a major early success in its inroads into cancer R&D through a sizable immuno-oncology deal with AbbVie, which also underscores the US firm’s push to expand its assets in the area.
Deal Watch: Novartis, Cerulean Team To Develop Nanoparticle-Drug Conjugates
Leveraging the brain power behind the first approved IPF drug, Esbriet, small companies Antegrin and Cascadia merge to form the fibrosis-centered Indalo Therapeutics. Gedeon Richter in-licenses a biosimilar of Roche’s Herceptin.
Asia Deal Watch: Inventiva Finds Japan/Korea Partner For Phase III NASH Candidate In Hepalys
Plus deals involving SK pharmteco/CBM, Kezar/Everest, Cerecin/University of Alberta, PeptiDream/Genentech, Aclipse/Chong Kun Dang and Cure Genetics/Frametact.